Background: We developed a hand-made silver container as a closed vitrification system (CVS) which avoid bacterial or viral contamination.
Objective: The aim of this study was to evaluate the preservation outcomes by comparing silver CVS and slow freezing (SF) method.
Materials And Methods: Donated human ovarian tissues were collected from nine patients. The fragments from each patient were randomly and evenly assigned to three groups: fresh control, silver CVS and SF group. The histology of the thawed ovarian tissue was investigated and the levels of secretion of estradiol (E2) and progesterone (P4) in the culture media were used to evaluate the development and function of thawed ovarian tissue.
Results: The results showed that the proportion of morphologically normal primordial follicles was higher in silver CVS group than in SF (P < 0.005). E2 and P4 concentrations were significantly higher in the silver CVS group than in the SF group at any time point after day 6 (E2: P < 0.05; P4: P < 0.05).
Conclusion: This study showed that human ovarian tissue cryopreserved with silver CVS had better morphology and higher E2 and P4 levels during in vitro ovarian tissue growth compared with SF. It implies that silver CVS has a better potential for ovarian tissue development in future clinical use.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Administrative Aspects of Molecular Diagnostics-Oversight, Regulatory Approval Process, Clinical and Operational Workflows, and Payment Models.
JCO Oncol Pract
November 2024
U.S. Food and Drug Administration, Silver Spring, MD.
This paper discusses the administrative aspects of molecular diagnostics in oncology, including US Food and Drug Administration (FDA) oversight, the regulatory approval process, clinical, and operational workflows, and payment models. Comprehensive molecular testing is important to deliver optimal oncology care and improve patient outcomes. Despite the potential benefits of testing, utilization remains low.
View Article and Find Full Text PDFFeasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials.
Cancer
January 2025
Brigham and Women's Hospital, Boston, Massachusetts, USA.
Background: The use of electronic health record (EHR) data for research is limited by a lack of structure and a standard data model. The objective of the ICAREdata (Integrating Clinical Trials and Real-World Endpoints Data) project was to structure key research data elements in EHRs using a minimal Common Oncology Data Elements (mCODE) data model to extract and transmit data.
Methods: The ICAREdata project captured two EHR data elements essential to clinical trials: cancer disease status and treatment plan change.
Real-world lessons: combining cancer registry and retail pharmacy data for oral cancer drugs.
J Natl Cancer Inst Monogr
August 2024
Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Background: Recent cancer care advances have introduced new oral therapies, and yet population registries lack detailed treatment data, hampering investigations into therapy uptake, adherence, and outcomes.
Objective: This study aimed to assess the representativeness and completeness of linking Surveillance, Epidemiology, and End Results (SEER) cancer registry data with data from two major retail pharmacy chains, collectively covering a large segment of the US market.
Methods: A deterministic data linkage between 11 SEER cancer registries and retail pharmacy data (excluding mail order fills) was conducted for individuals diagnosed with selected cancers from 2013 to 2017, with follow-up through 2019.
Background: Pulmonary hypertension (PH) accompanying COPD (PH-COPD) is associated with worse outcomes than COPD alone. There are currently no approved therapies to treat PH-COPD. The PERFECT study (ClinicalTrials.
View Article and Find Full Text PDFEffectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study.
BMC Pediatr
April 2024
US Food and Drug Administration, Silver Spring, MD, USA.
Background: COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. This study's objective was to estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children.
Methods: This cohort study identified children aged 5-17 years vaccinated with BNT162b2 matched with unvaccinated children.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!